Month: September 2026

Separation Would Create Two High-Quality Public Companies, Each With Distinct Growth Strategies and Long-Term Value Creation Opportunities

• National Fuel’s Integrated Upstream and Gathering business would become an independent public company focused solely on its highly integrated, Appalachian upstream and gathering natural gas business.
• Post-separation, National Fuel would be a 100% rate-regulated company with natural gas utility and interstate pipeline and storage assets across Pennsylvania, Ohio, and New York.
• The separation would be effected through a tax-free distribution of shares to National Fuel shareholders.
• National Fuel expects to conclude its evaluation by October 15, 2026.

WILLIAMSVILLE, N.Y., Sept. 17, 2026 (GLOBE NEWSWIRE) — National Fuel Gas Company (NYSE: NFG) (“National Fuel” or the “Company”) announced that by October 15, 2026 its Board of Directors intends to complete an ongoing evaluation of a plan to separate the Company into two independent publicly traded companies, which remains subject to final Board approval.

If pursued and upon completion of the transaction, National Fuel shareholders would own shares in both National Fuel and its Integrated Upstream and Gathering (“IUG”) business, creating two focused companies, each with significant scale, strong financial profiles, and distinct growth opportunities. As independent entities, each publicly traded company would be well positioned to deliver long-term growth and sustainable value creation for investors, customers, and employees, with the standalone businesses expected to benefit from:

• Greater capital allocation flexibility to pursue each company’s distinct growth opportunities and shareholder return priorities, supported by highly experienced leadership teams, strong balance sheets, and more tailored capital structures.
• Preserving the key benefits of integration that each business realizes today, including the capital efficiencies provided by IUG’s integrated upstream and gathering operations, and critical operating synergies that support customer affordability and commercial benefits across National Fuel’s regulated businesses.
• Potentially more compelling equity stories that increase visibility among relevant investors and research analysts and align each public company with its natural investor base.

“National Fuel has benefitted for many years from the strength and diversification of our integrated business model, which provided the financial capacity and cash flow generation to support significant strategic investments across the Company, including multiple transformative acquisitions since 2020,” said David P. Bauer, President and Chief Executive Officer of National Fuel. “Over that same period, the capital markets and operating environment of our regulated and non-regulated natural gas businesses have evolved meaningfully. With the expected closing of our Ohio gas utility acquisition next month, each business will be a scaled platform with distinct strategic priorities, organic growth opportunities, capital needs, and investment profiles.”

If approved, National Fuel would separate IUG through a distribution of shares of IUG to National Fuel shareholders in a manner which would be intended to be tax-free for National Fuel and its shareholders for U.S. federal income tax purposes.

National Fuel: 100% regulated natural gas platform, with a highly-strategic, growing integrated utility and interstate pipeline and storage assets in constructive regulatory jurisdictions

If a separation is pursued, National Fuel would be a fully-regulated natural gas business with nearly $5 billion of rate base.¹ Its utility business would serve 1.1 million customers across Ohio, New York and Pennsylvania. In addition, the FERC-regulated pipeline and storage business would provide nearly 5 Bcf per day of contracted natural gas transportation capacity and 77 Bcf of fully-contracted natural gas storage services.

National Fuel operates across constructive regulatory jurisdictions, with significant long-term investment opportunities, supported by ongoing infrastructure modernization programs and increased natural gas demand accelerating the need for new pipeline and storage infrastructure. Together, these dynamics support continued investment in existing pipeline systems, as well as the ongoing execution of transmission and storage expansions to support growing demand.

National Fuel would benefit from a strong balance sheet and investment grade credit metrics expected to be in line with some of the strongest in the utility sector, with no need to raise incremental equity capital expected over the next five years based on current capital plans. This could potentially provide the company with significant financial flexibility to fund its growth plans and position it to execute on its long-term growth opportunities.

Integrated Upstream and Gathering: A premier, integrated Appalachian natural gas business with high-quality assets, and best-in-class inventory depth and capital efficiency trends

If a separation is pursued, IUG will be a leading integrated, low-cost, upstream natural gas business, with approximately 1.2 million total net acres in Appalachia and approximately 1.1 Bcf per day of net natural gas production. IUG owns significant integrated gathering assets that transport the vast majority of its production, providing greater operational control, cost certainty, and alignment across its operating footprint. With approximately 5 Tcf of natural gas reserves and more than 40 years of prospective Marcellus and Utica development inventory, IUG would be well positioned to grow production, extend its track record of operational improvement, and create long-term value through disciplined capital allocation.

Since transitioning its development program to the Eastern Development Area in 2023, IUG has delivered industry-leading capital efficiency improvements of approximately 25%, enabling IUG to generate increased production and free cash flow per dollar invested while enhancing potential shareholder returns. Combined with its integrated gathering platform and portfolio of firm transportation capacity that provides access to premium markets, IUG would be expected to maintain a best-in-class operating cost structure and market access advantages that support long-term value creation.

Advisors

Goldman Sachs & Co. LLC is serving as financial advisor to National Fuel, and Skadden, Arps, Slate, Meagher & Flom LLP is serving as legal counsel.

About National Fuel Gas Company
National Fuel is a diversified energy company headquartered in Western New York that currently operates an integrated collection of natural gas assets across three operating segments: Integrated Upstream and Gathering, Pipeline and Storage, and Utility. Additional information about National Fuel is available at www.nationalfuel.com.

Cautionary Statements
Certain statements contained herein, including statements identified by the use of the words “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “guidance,” “intends,” “may,” “might,” “outlook,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “targets,” “will,” “would”, and variations of such words and similar future or conditional expressions, and statements which are other than statements of historical facts, are intended to identify “forward-looking statements” as defined under U.S. federal securities laws, including, but not limited to, statements, estimates, and projections relating to the potential separation of the Company into two companies (the “Separation”), including the timing and structure of the Separation, the characteristics of the separated businesses, and the expected benefits of the Separation, future operating and financial performance and long-term strategy, and the assumptions underlying such expected benefits, targets, strategies, and statements. These forward-looking statements are based on management’s beliefs, expectations, estimates, and projections at the time they are made and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties, which could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. The Company’s expectations, beliefs, and projections contained herein are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that such expectations, beliefs, or projections will result or be achieved or accomplished. There can be no guarantees with respect to whether the Separation will be completed. In addition to other factors, the following are among the important factors that could cause actual results to differ materially from those discussed in the forward-looking statements: the ability to effect the Separation and to meet the conditions related thereto; the ability to obtain any consents or approvals required to complete the Separation; the ability of the separated companies to each succeed as standalone publicly traded companies; negative effects of the announcement or pendency of the Separation on the market price of the Company’s securities and/or on the Company’s financial performance; the possibility that the Separation will not achieve its intended benefits; the possibility of disruption, including disputes, litigation, or unanticipated costs in connection with the Separation; the impact of the Separation on the Company’s businesses and the risk that the Separation may be more difficult, time-consuming, or costly than expected, including the impact on the Company’s resources, systems, procedures, and controls, diversion of management’s attention, and the impact and possible disruption of existing relationships with regulators, customers, suppliers, employees, and other business counterparties; the ability to achieve anticipated capital structures in connection with the Separation; the ability to achieve anticipated credit ratings in connection with the Separation; the ability to achieve anticipated tax treatments in connection with the Separation and future, if any, divestitures, mergers, acquisitions, and other portfolio changes, and the impact of changes in relevant tax and other laws and regulations; changes in laws, regulations, or judicial interpretations to which the Company is subject, including those involving derivatives, taxes, safety, employment, climate change, other environmental matters, real property, and exploration and production activities such as hydraulic fracturing; governmental/regulatory actions, initiatives, and proceedings, including those involving rate cases (which address, among other things, target rates of return, rate design, retained natural gas, and system modernization), environmental/safety requirements, affiliate relationships, industry structure, and franchise renewal; changes in economic conditions, including the imposition of additional tariffs on U.S. imports and related retaliatory tariffs, inflationary pressures, supply chain issues, liquidity challenges, and global, national, or regional recessions, and their effect on the demand for, and customers’ ability to pay for, the Company’s products and services; the Company’s ability to complete strategic transactions, and to recognize the anticipated benefits of such transactions; governmental/regulatory actions and/or market pressures to reduce or eliminate reliance on natural gas; the Company’s ability to estimate accurately the time and resources necessary to meet emissions targets; changes in the price of natural gas; impairments under the SEC’s full cost ceiling test for natural gas reserves; the creditworthiness or performance of the Company’s key suppliers, customers, and counterparties; financial and economic conditions, including the availability of credit, and occurrences affecting the Company’s ability to obtain financing on acceptable terms for working capital, capital expenditures, other investments, and acquisitions, including any downgrades in the Company’s credit ratings and changes in interest rates and other capital market conditions; negotiations with the collective bargaining units representing the Company’s workforce, including potential work stoppages during negotiations; changes in price differentials between similar quantities of natural gas sold at different geographic locations, and the effect of such changes on commodity production, revenues, and demand for pipeline transportation capacity to or from such locations; the impact of information technology disruptions, cybersecurity, or data security breaches, including the impact of issues that may arise from the use of artificial intelligence technologies; factors affecting the Company’s ability to successfully identify, drill for, and produce economically viable natural gas reserves, including, among others, geology, lease availability and costs, title disputes, weather conditions, water availability and disposal or recycling opportunities of used water, shortages, delays, or unavailability of equipment and services required in drilling operations, insufficient gathering, processing, and transportation capacity, the need to obtain governmental approvals and permits, and compliance with environmental laws and regulations; increased costs, delays, or changes in plans with respect to Company projects or related projects of other companies, as well as difficulties or delays in obtaining necessary governmental approvals, permits or orders or in obtaining the cooperation of interconnecting facility operators; increasing health care costs and the resulting effect on health insurance premiums and on the obligation to provide other post-retirement benefits; other changes in price differentials between similar quantities of natural gas having different quality, heating value, hydrocarbon mix or delivery date; the cost and effects of legal and administrative claims against the Company or activist shareholder campaigns to effect changes at the Company; uncertainty of natural gas reserve estimates; significant differences between the Company’s projected and actual production levels for natural gas; changes in demographic patterns and weather conditions, including those related to climate change; changes in the availability, price, or accounting treatment of derivative financial instruments; changes in laws, actuarial assumptions, the interest rate environment, and the return on plan/trust assets related to the Company’s pension and other post-retirement benefits, which can affect future funding obligations and costs and plan liabilities; economic disruptions or uninsured losses resulting from major accidents, fires, severe weather, natural disasters, terrorist activities, or acts of war, as well as economic and operational disruptions due to third-party outages; significant differences between the Company’s projected and actual capital expenditures and operating expenses; increasing costs of insurance, changes in coverage, and the ability to obtain insurance; other factors described in the risk factors set forth in the Company’s filings with the U.S. Securities and Exchange Commission, including the Company’s most recently filed Annual Report on Form 10-K and subsequent Current Reports on Form 8-K and Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation, and disclaims any duty, to update, revise, or withdraw any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by applicable law or regulation.

¹ Projected as of December 31, 2026 and assumes the October 1, 2026 closing of National Fuel’s previously announced acquisition of CenterPoint’s Ohio natural gas utility business.

Analyst Contact: Ryan Vossler | 716-857-7158
Media Contact: Karen Merkel | 716-857-7654

Findings Strengthen Telomir-Zn’s Oncology-Focused Platform While Demonstrating Broader Relevance of Its Metal-Dependent Epigenetic Biology

MIAMI, Sept. 17, 2026 (GLOBE NEWSWIRE) — Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, today announced the peer-reviewed publication of new preclinical research showing that Telomir-Zn significantly improved visual function, restored retinal structure, and reduced mitochondrial oxidative stress in a model of age-related macular degeneration (AMD).

The findings extend the scientific understanding of Telomir-Zn beyond oncology, providing new evidence that modulation of intracellular metal homeostasis may influence disease-associated pathways across substantially different biological settings. In the AMD model, Telomir-Zn improved visual performance and retinal structure and was associated with restoration of altered DNA methylation patterns and a dose-dependent increase in relative telomeric DNA content toward the profile observed in healthy animals.

Complementary mechanistic studies showed that Telomir-Zn reduced intracellular labile iron and potently inhibited iron-dependent Jumonji C histone demethylases (KDMs), enzymes that help regulate which genes cells turn on or off. The findings provide a potential mechanistic link between Telomir-Zn’s effects on intracellular metals and its emerging role in epigenetic regulation. In retinal degeneration, this biology may be particularly relevant to cellular programs involved in inflammation, senescence, DNA repair, and survival as retinal cells respond to oxidative and mitochondrial stress.

Telomir’s clinical development remains focused on oncology, with Telomir-Zn advancing under an FDA-cleared Investigational New Drug application for a Phase 1/2 clinical trial in patients with advanced or metastatic triple-negative breast cancer (TNBC). The new retinal findings add to a growing body of published research supporting a common upstream biology centered on intracellular metal homeostasis and epigenetic regulation, while demonstrating that the biological relevance of Telomir-Zn may extend beyond the Company’s current clinical development focus.

The manuscript, titled “Targeted Intracellular Metal Modulation Attenuates Oxidative Stress and Preserves Retinal Integrity and Function in a Zebrafish Model of Mitochondrial Dysfunction and Age-Related Retinal Degeneration,” was published in International Journal of Molecular Sciences. 2026, 27(18), 8265; DOI: 10.3390/ijms27188265.

Publication Highlights

Improved Visual Function and Reduced Retinal Degeneration

Untreated animals in the accelerated retinal degeneration model exhibited profound visual impairment, photoreceptor loss, retinal pigment epithelium disruption, and degeneration of multiple retinal layers.

After 14 days of oral treatment, Telomir-Zn significantly improved central visual response, moving-object tracking, and adaptation to changes in light intensity. Histological analysis demonstrated significant improvement in retinal degeneration, with restoration of thickness across multiple retinal layers, including the outer and inner nuclear layers, outer plexiform layer, and ganglion cell layer.

Reduced Mitochondrial Oxidative Stress and Protected Human Retinal Cells

The AMD model exhibited markedly elevated oxidative stress associated with mitochondrial dysfunction. Telomir-Zn significantly reduced brain reactive oxygen species, used in the study as a surrogate measure of mitochondrial oxidative stress, with the higher dose restoring values toward wild-type baseline.

In complementary experiments using human ARPE-19 retinal pigment epithelial cells, Telomir-Zn dose-dependently attenuated iron- and copper-induced calcium dysregulation and reduced copper-induced intracellular reactive oxygen species toward baseline.

Together, these findings demonstrate activity across two biologically relevant settings: reduction of mitochondrial oxidative stress in vivo and protection against metal-induced oxidative and calcium stress in human retinal cells. This is particularly relevant because oxidative stress, mitochondrial dysfunction, and metal dysregulation are central features of the retinal degeneration biology examined in the study.

Epigenetic and Telomere-Associated Changes

Telomeres are protective DNA sequences at the ends of chromosomes that are closely associated with cellular aging and genomic stability. In the accelerated retinal degeneration model, relative telomeric DNA content was significantly reduced compared with healthy wild-type animals, consistent with the model’s accelerated degenerative state.

Following Telomir-Zn treatment, relative telomeric DNA content increased dose-dependently toward the healthier profile observed in wild-type animals. Treatment was also associated with restoration of altered DNA methylation patterns at selected aging-associated CpG loci.

Together, these findings suggest that Telomir-Zn’s biological activity may extend beyond reducing oxidative stress to broader genomic and epigenetic processes associated with cellular aging and degeneration.

A Common Metal-Dependent Epigenetic Biology

Separate cellular studies described in the manuscript demonstrated that Telomir-Zn increased intracellular zinc while reducing labile Fe²⁺. Biochemical assays also demonstrated potent inhibition of multiple Fe²⁺-dependent Jumonji C histone demethylases across the KDM2, KDM5, and KDM6 families, with the strongest activity observed against KDM5B at an IC50 of 63 nM.

Most KDMs are iron-dependent enzymes that help regulate which genes cells turn on or off through changes in histone methylation. These enzymes influence cellular programs involved in inflammation, senescence, DNA repair, and cell survival. Because the KDMs evaluated in the study require Fe²⁺ for catalytic activity, reducing labile intracellular Fe²⁺ provides a potential upstream mechanism through which Telomir-Zn may influence disease-associated epigenetic programs.

In retinal degeneration, this may be particularly relevant because oxidative and mitochondrial stress can alter cellular programs governing inflammation, senescence, DNA repair, and survival. By changing the intracellular metal environment and inhibiting iron-dependent epigenetic enzymes, Telomir-Zn may help shift stressed cells toward a more protective epigenetic state.

The findings build upon Telomir-Zn’s previously published oncology research, where intracellular labile iron reduction and inhibition of iron-dependent KDMs were associated with epigenetic reprogramming and anti-tumor activity. In TNBC cells, iron-rescue experiments showed that adding iron back significantly reversed Telomir-Zn’s anti-cancer effect, directly linking iron availability to the compound’s activity.

Together, the published findings support an emerging biological framework in which Telomir-Zn modulates the intracellular metal environment to influence epigenetic machinery and downstream disease-associated cellular programs. The biological consequences may differ by disease—potentially disrupting pathways supporting tumor growth and survival in cancer while contributing to a more protective cellular environment under conditions of oxidative and mitochondrial stress in retinal degeneration.

This common metal-dependent epigenetic biology provides a potential explanation for why Telomir-Zn has demonstrated biological activity across substantially different preclinical disease settings, while the Company remains focused on advancing its clinical development program in oncology.

Management Commentary

“This study gives us an important new view of the relationship between intracellular metal balance, oxidative stress, epigenetic regulation and retinal degeneration,” said Dr. Itzchak Angel, Chief Scientific Advisor of Telomir. “Telomir-Zn significantly improved visual function, reduced retinal degeneration, and restored key retinal-layer thicknesses, supporting the potential relevance in a devastating disease such as AMD, beyond oncology.”

“Our clinical priority remains oncology, beginning with our FDA-cleared Phase 1/2 program in TNBC, but we believe the potential opportunity for Telomir-Zn could extend well beyond a single indication,” said Erez Aminov, CEO of Telomir. “As we build evidence across different disease models, we are seeing a common biology centered on intracellular metal homeostasis and epigenetic regulation. We believe this creates meaningful platform potential for Telomir-Zn across additional cancers and, over time, other diseases where this biology may play an important role.”

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer. The Company’s lead program, Telomir-Zn, is designed to modulate intracellular metal homeostasis and epigenetic regulation and has received Investigational New Drug clearance from the U.S. Food and Drug Administration for a Phase 1/2 clinical trial in patients with advanced or metastatic triple-negative breast cancer. For more information, please visit https://telomirpharma.com/.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential,” “intend,” “seek,” “target” and other words of similar meaning, although not all forward-looking statements include these words.

Forward-looking statements may include, but are not limited to, statements regarding the therapeutic potential, mechanism of action, development plans, regulatory pathway, safety profile, clinical utility, market opportunity, and future development of Telomir-1 (Telomir-Zn) and the Company’s other product candidates. Forward-looking statements may also include statements regarding the significance of the published preclinical findings, the relevance of such findings to the Company’s oncology development programs, the advancement of the Company’s Phase 1/2 TNBC clinical trial, and the potential applicability of Telomir-Zn across multiple disease areas.

These forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as management’s beliefs and assumptions, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to preclinical and clinical development, the ability to obtain regulatory approvals, the outcome of future studies, reliance on third parties, intellectual property protection, financing needs, market conditions, and the other risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission (“SEC”).

Forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update or revise such statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at the SEC website and in the “Investors” section of our website, for a discussion of these and other risks and uncertainties.

Contact Information

Krystina Quintana
Email: info@telomirpharma.com
Phone: (786) 396-6723

NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) — Saratoga Investment Corp. (NYSE:SAR), a business development company, will report its financial results for the fiscal quarter ended August 31, 2026, on Tuesday October 6, 2026, after market close. A conference call to discuss the financial results will be held on Wednesday October 7, 2026. Details for the conference call are provided below.

Who:	Christian L. Oberbeck, Chairman and Chief Executive Officer
	David DeSantis, Chief Operating Officer, Portfolio Manager, and Senior Managing Director
	Henri J. Steenkamp, Chief Financial Officer, Chief Compliance Officer, Treasurer and Secretary
When:	Wednesday, October 7, 2026
	10:00 a.m. Eastern Time (ET)
How:	Webcast: Interested parties may access a live webcast of the call and find the Q2 2027 presentation by going to the “Events & Presentations” section of Saratoga Investment Corp.’s investor relations website, Saratoga events and presentations. A replay of the webcast will also be available for a limited time at Saratoga events and presentations.
	Call: To access the call by phone, please go to Registration Link, and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time.
Information:	Saratoga Investment Corp.’s Form 10-Q for the fiscal quarter ended August 31, 2026, will be filed on October 6, 2026, with the Securities and Exchange Commission.

About Saratoga Investment Corp.

Saratoga Investment is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests primarily in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Saratoga Investment’s objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments. Saratoga Investment has elected to be regulated as a business development company under the Investment Company Act of 1940 and is externally managed by Saratoga Investment Advisors, LLC, an SEC-registered investment advisor focusing on credit-driven strategies. Saratoga Investment Corp. owns two active SBIC-licensed subsidiaries, having surrendered its first license after repaying all debentures for that fund following the end of its investment period and subsequent wind-down. Furthermore, it manages a $350 million collateralized loan obligation (“CLO”) fund that has recently repriced and reset its reinvestment period and co-manages a joint venture (“JV”) fund that owns a $400 million collateralized loan obligation (“JV CLO”) fund.  It also owns 52% of the Class F and 100% of the subordinated notes of the CLO, 87.5% of both the unsecured loans and membership interests of the JV and 87.5% of the Class E-R notes of the JV CLO. The Company’s diverse funding sources, combined with a permanent capital base, enable Saratoga Investment to provide a broad range of financing solutions.

Contact:

Henri Steenkamp
Saratoga Investment Corp.
212-906-7800

Proven Commercial Leader Has Helped Drive Growth of the Company’s Core Herb Business While Laying the Foundation for Its Farm-to-Formula® Ready-to-Drink Platform

BELVIDERE, NJ, Sept. 17, 2026 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), organic and sustainable produce, and developer of the Zero-Waste Inspired^® mission and Farm-to-Formula^® platform, today announced the promotion of David Ross to Senior Vice President of Sales and Marketing.

Mr. Ross was appointed Vice President of Sales and Marketing in June 2023 after previously serving as the Company’s Director of Sales and Marketing. During his tenure, he has played a key role in growing Edible Garden’s fresh produce business, strengthening relationships with major retailers, expanding customer programs, and broadening the Company’s retail presence.

Building on that success, Mr. Ross has also helped lay the commercial foundation for Edible Garden’s Farm-to-Formula® strategy and planned expansion into clean-label ready-to-drink (“RTD”) nutrition products. Edible Garden is developing its Prairie Hills facility in Webster City, Iowa, as a dedicated clean-nutrition RTD manufacturing hub. In his expanded role, Mr. Ross will continue to lead sales and marketing while taking on greater responsibility for retailer engagement, product positioning and commercialization of products expected to be manufactured in Iowa.

“Dave has been a driving force behind the growth of our core herb business and has consistently demonstrated an ability to translate strong retailer relationships into meaningful commercial opportunities,” said Jim Kras, Chief Executive Officer of Edible Garden. “His promotion recognizes those accomplishments as well as the important role he is playing in helping us build the commercial foundation for our next phase of growth. As we advance our Farm-to-Formula® strategy and expand our capabilities in Iowa, we believe Dave’s understanding of our customers, categories and consumers will be invaluable in helping us identify opportunities and bring new products to market that are aligned with real retailer and consumer demand.”

“I am honored to take on this expanded role and excited about the opportunities ahead,” said Mr. Ross. “I look forward to building on the momentum in our fresh produce business while working with our team and retail partners to bring our Farm-to-Formula® strategy to market through compelling clean-label products that meet the evolving needs of retailers and consumers.”

ABOUT EDIBLE GARDEN^®

Edible Garden AG Incorporated is a leader in controlled environment agriculture (CEA), delivering organic, better-for-you, sustainable produce and products through its Zero-Waste Inspired^® next-generation farming model. Available in over 6,000 retail locations across the United States, Caribbean, and South America, Edible Garden is at the forefront of the CEA and sustainability technology movement, distinguished by its advanced safety-in-farming protocols, sustainable packaging, patented GreenThumb software, and innovative Self-Watering in-store displays. The Company operates state-of-the-art, vertically integrated greenhouses and processing facilities, including Edible Garden Heartland in Grand Rapids, Michigan; Edible Garden Prairie Hills in Webster City, Iowa; and its headquarters at Edible Garden Belvidere in New Jersey. It also partners with a network of contract growers strategically located near major U.S. markets to ensure freshness and reduce environmental impact. The Company is also expanding its Prairie Hills facility in Webster City, Iowa, into a dedicated ready-to-drink (RTD) clean nutrition manufacturing hub, supporting its Farm-to-Formula® strategy and its transformation into higher-margin, shelf-stable nutrition categories.

Edible Garden’s proprietary GreenThumb 2.0 software—protected by U.S. Patents US 11,158,006 B1, US 11,410,249 B2, and US 11,830,088 B2—optimizes vertical and traditional greenhouse growing conditions while aiming to reduce food miles. Its patented Self-Watering display (U.S. Patent No. D1,010,365) is designed to extend plant shelf life and elevate in-store presentation. In addition to its core CEA operations, Edible Garden owns three patents in advanced aquaculture technologies: a closed-loop shrimp farming system (US 6,615,767 B1), a modular recirculating aquaculture setup with automated water treatment and feeding (US 10,163,199 B2), and a sensor-driven ammonia control method utilizing electrolytic chlorine generation (US 11,297,809 B1).

The Company has been recognized as a FoodTech 500 firm by Forward Fooding, is a multi-year participant in Walmart’s Project Gigaton and a Giga Guru designee and has received NRG’s Excellence in Energy Award for its commitment to measurable environmental performance and energy stewardship. Edible Garden also develops and markets a growing line of nutrition and specialty food products, including Vitamin Way^® and Vitamin Whey^®—plant and whey protein powders—and Kick. Sports Nutrition, a premium performance line for health-conscious athletes seeking cleaner, better-for-you options. The Company’s offerings further include fresh, sustainable condiments such as Pulp fermented gourmet and chili-based sauces, as well as Pickle Party, a collection of fermented fresh pickles and krauts.

Learn more at https://ediblegardenag.com.
For Pulp products, visit https://www.pulpflavors.com.
For Vitamin Whey® products, visit https://vitaminwhey.com.
For Kick. Sports Nutrition products, visit https://kicksportsnutrition.net/.
Watch the Company’s latest corporate video here.

FORWARD-LOOKING STATEMENTS
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “expand,” “extend,” “transform,” “strategy,” “advance,” “create,” “initiative,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. These statements include, without limitation, statements regarding the Company’s ability to expand and strengthen its operations, the development of the Company’s ready-to-drink manufacturing facility in Webster City, Iowa, and the Company’s Farm-to-Formula® strategy. Forward-looking statements are based on the Company’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including those described in the “Risk Factors” section and other sections of the Company’s reports filed with the Securities and Exchange Commission. All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no duty to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contacts:
Crescendo Communications, LLC
212-671-1020
EDBL@crescendo-ir.com

Justin Mennen to Succeed Leslie C.G. Campbell as Chair of the Board Following Her Retirement

DELRAY BEACH, Fla., Sept. 17, 2026 (GLOBE NEWSWIRE) — PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced the appointment of consumer and e-commerce sector veteran, Jeff Willard, as Chief Executive Officer and President, as well as a member of the Board of Directors, effective September 28, 2026. Mr. Willard succeeds Leslie C.G. Campbell, who, in addition to serving as Chair of the Board of PetMeds, has served as Interim Chief Executive Officer and President since August 2025.

Mr. Willard brings more than 25 years of proven leadership experience at leading consumer and e-commerce companies, with a distinguished track record of driving sustainable growth, optimizing operational performance and building brands. Most recently, he has served as CEO of Stewart-MacDonald (StewMac), a leading global e-commerce provider of guitar tools and parts. Prior to that, he served as Chief Growth Officer and Chief Marketing Officer of Casper, President of Healthy Lifestyle Brands, and CEO of Zac Brown Collective. Earlier in his career, he held senior executive leadership roles at Simmons Bedding Company, Harman International, Coleman, Helen of Troy, and Lexmark International.

“After a thorough and deliberate search, the Board is confident that Jeff is the right leader to guide PetMeds into its next chapter,” said Ms. Campbell. “Jeff brings a proven track record of scaling consumer brands and driving operational discipline across businesses of varying size and complexity. That expertise is exactly what PetMeds needs today. The strategic, operational, and cultural improvements we have made over the past year provide a solid foundation for this transition, and our entire Board looks forward to working closely with Jeff to build long-term value for our shareholders.”

“I’m excited to join PetMeds at such a pivotal moment for the Company,” said Jeff Willard, incoming Chief Executive Officer and President of PetMeds. “As an owner of two older rescue dogs, I know firsthand that Pet parents build their whole lives around the health and wellbeing of their animals, and it’s our shared mission that puts PetMeds at the center of that trust. The team has done exceptional work stabilizing the foundation, and my primary focus now is on sharpening our execution and establishing a direct, clear path back to sustainable profitability and growth. I look forward to partnering with the Board and leading our talented team to accelerate our progress, unlock PetMeds’ full potential, and deliver long-term value for our shareholders.”

Board Leadership Transition

With the successful completion of the search for and appointment of the new CEO, Ms. Campbell has informed the Board of her decision to retire as Chair and step down from the Board, effective September 28, 2026. The Board has appointed Justin Mennen, currently the Lead Independent Director and Chair of the Corporate Governance and Nominating Committee, to succeed Ms. Campbell as Chair, effective September 28, 2026. In addition, effective September 28, 2026, Peter Batushansky, a current member of the Corporate Governance and Nominating Committee, will succeed Mr. Mennen as Committee Chair. Mr. Mennen will step down as Chair of the committee on that date but will remain a member. Mr. Mennen currently serves as Chief Information and Technology Officer of Shake Shack Inc. and has served on the PetMeds Board since June 2024. He has been a member of the Audit Committee since June 2024 and became Chair of the Corporate Governance and Nominating Committee, and Lead Independent Director, in August 2025.

At the Board’s request, Ms. Campbell will remain with PetMeds as a full-time Strategic Advisor to the Company for 60 days following Mr. Willard’s arrival. In this role, she will leverage her deep institutional knowledge and strong relationships with key strategic partners, shareholders, and other stakeholders to maintain momentum on key business priorities and provide vital continuity. Her ongoing involvement and guidance will also ensure a seamless and orderly transition for both Mr. Mennen in his new Board Chair role and Mr. Willard as CEO and President. Ms. Campbell has served as a member of the Board, including as committee chair of each of the standing committees at different times since 2018, stepping into the role of Board Chair in January 2024. She has also served as Interim Chief Executive Officer and President since August 2025.

“It has been a privilege to serve on the Board, and this past year as Interim CEO to lead PetMeds through such a critical period in its history,” said Ms. Campbell. “I am immensely proud of what our team has accomplished in strengthening our culture, governance, and operations, and sharpening our strategic focus on long-term value creation. With Jeff taking the helm and a strong Board in place, I feel confident that the Company is well positioned for its next chapter.”

“On behalf of the entire Board, I want to extend our sincere gratitude to Leslie for her leadership and tireless dedication to PetMeds,” said Mr. Mennen, incoming Chair of the Board of PetMeds. “Her steadfast guidance and unwavering commitment to our employees, customers, and shareholders navigated the Company through an important period of transformation. We are deeply grateful for her invaluable contributions and know she will remain a lifelong champion of PetMeds.”

About PetMeds

Founded in 1996, PetMeds is a pioneer in the direct-to-consumer pet healthcare sector. As a trusted national online pharmacy, PetMeds is licensed across all 50 states and staffed with expert pharmacists dedicated to supporting pet wellness, pets and pet parents, and the veterinarians who serve them. Through its PetMeds family of brands and through its PetCareRx subsidiary, the Company offers a comprehensive range of pet health solutions — including top-brand and generic pharmaceuticals, compounded medications, and better-for-your-pet OTC supplements and nutrition. Focused on value, convenience, and care, PetMeds and PetCareRx empower pet parents to help their dogs, cats, and horses live longer, healthier lives. To learn more, visit www.PetMeds.com and www.PetCareRx.com.

Forward-Looking Statements

This press release may contain “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties, including the Company’s ability to meet the objectives included in its business plan. These forward-looking statements include, without limitation, statements regarding the Company’s potential, the foundation in place for the Company’s growth and ability to deliver long-term value for the Company’s shareholders; and the Company’s ability to scale, execute on its long-term growth priorities, sharpen its execution, return to sustainable profitability and growth, maintain critical momentum on key business priorities, and ensure a seamless transition of its leadership. Important factors that could cause results to differ materially from those indicated by such forward-looking statements are set forth in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in the Company’s Annual Report on Form 10-K filed on June 2, 2026 for the fiscal year ended March 31, 2026. The Company’s future results may also be impacted by other risk factors listed from time to time in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, the Company’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements, other than as may be required by law. If the Company does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.

Investor Contact
ICR, LLC
Reed Anderson
investor@petmeds.com

New double grande suite floor plan targets growing demand for multigenerational living

PHOENIX, Sept. 17, 2026 (GLOBE NEWSWIRE) — Cavco Industries, Inc. (Nasdaq: CVCO) will debut the first manufactured home constructed without a permanent steel chassis frame built to the U.S. Department of Housing and Urban Development (HUD) Code, at the 2026 Innovative Housing Showcase on the National Mall in Washington, D.C., September 22-24.

The annual showcase, organized by HUD, highlights housing designs and technologies intended to increase the supply of homes and lower costs for owners and renters. The showcase draws policymakers, industry leaders, members of Congress and the public for tours of model homes, as well as educational discussion panels on housing affordability.

On July 11, 2026, the passing of the bipartisan 21^st Century ROAD to Housing Act eliminated the federal chassis mandate for HUD-code housing, expanding building options for buyers, builders and communities. Building HUD-code homes without a permanent steel chassis allows for lower-profile installation. This ground set capability provides improved curb appeal for smooth integration into traditional neighborhoods, access to new urban and suburban markets and developments, as well as greater design flexibility including multi-story construction.

Cavco’s new frameless display home, the Grande Arbor, introduces a double grande suite floor plan, placing two primary suites at opposite ends of the home. These private areas are connected by a shared kitchen, dining and living space designed to meet the needs of households looking for multigenerational housing options. According to the Pew Research Center, about 22% of Americans – more than 74 million people – currently live in a multigenerational household. The National Association of Realtors reported that in 2024, 17% of homes purchased in the U.S. were bought specifically for multigenerational use, the highest share on record. Aging parents, adult children returning home and the rising cost of maintaining separate households are among the factors driving the trend.

“Addressing the affordable housing crisis remains a top priority for our company,” said Bill Boor, Cavco President and CEO. “Innovation and advocacy for manufactured housing at the national and local level go hand in hand. That’s why events like the Innovative Housing Showcase are so important. Policy makers and others can see for themselves the homes we are developing to meet buyers’ needs while keeping prices affordable. The Grande Arbor does both, and we’re proud to showcase it this year.”

Cavco is co-exhibiting the Grande Arbor with UMH Properties Inc. (Nasdaq: UMH). The Grande Arbor, built by their Cavco – Rocky Mount, Virginia team, is Cavco’s latest in a series of firsts aimed at expanding affordable housing options. In 2023, Cavco – Rocky Mount also built and introduced the Anthem – the first nationally available manufactured duplex approved by HUD.

About Cavco

Headquartered in Phoenix, Arizona, Cavco Industries, Inc. (Nasdaq: CVCO) designs and builds manufactured homes and modular homes, distributed nationwide through a network of independent and Company-owned retailers. Cavco is one of the largest manufactured and modular home builders in the United States, based on reported wholesale shipments, and is also a leading producer of park model RVs, vacation cabins, and factory-built commercial structures.

Cavco’s finance subsidiary, CountryPlace Mortgage, is an approved Fannie Mae and Freddie Mac seller/servicer and a Ginnie Mae mortgage-backed securities issuer, offering manufactured home loans — including conforming, non-conforming, and home-only financing — to buyers of manufactured and modular homes. Cavco’s insurance subsidiary, Standard Casualty, provides manufactured home insurance and other property and casualty coverage to manufactured homeowners.

Learn more about Cavco’s manufactured homes and modular homes at www.cavcohomes.com.

For additional information, contact:

Colleen Rogers
SVP – Marketing & Communications
Email: media@cavco.com
Phone: 972-763-5038
Website: www.cavcohomes.com

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/625486f8-d8ea-4ff1-a1ac-a29250bcfe86
https://www.globenewswire.com/NewsRoom/AttachmentNg/450a04df-7602-45c8-949a-7855cdfc5a6a 

Expansion of domestic production of advanced conductive additives for next-generation battery applications to support growth in energy storage, AI infrastructure, and electrification

BOSTON, Sept. 17, 2026 (GLOBE NEWSWIRE) — Cabot Corporation (NYSE: CBT) today announced a modified $50 million grant from the U.S. Department of Energy’s (DOE) Office of Critical Minerals and Energy Innovation (CMEI) that will support the company’s recently announced plans to expand its North American battery materials platform. Supported by this DOE grant and approximately $75 million of Cabot investment, the company plans to expand domestic production of advanced conductive additives at its facilities in Franklin, Louisiana, and Pampa, Texas. The planned investments are designed to address rising demand for advanced battery materials driven by the expansion of energy storage systems, increasing power requirements from artificial intelligence (AI) infrastructure and data centers, ongoing grid modernization efforts, and broader electrification trends. It will support this growing demand while expanding domestic production of critical conductive additives in the United States.

The grant reflects a collaborative effort between Cabot and DOE to redirect funding from the company’s originally announced Michigan project to a two-site brownfield expansion program. By leveraging existing manufacturing assets, Cabot expects to accelerate the development of a local and secure supply of critical conductive additives for the growing domestic battery supply chain while strengthening its ability to serve customers globally. The planned investments are also expected to support high-quality manufacturing and construction jobs and contribute to U.S. leadership in advanced battery materials technologies.

Cabot is well-positioned to capitalize on growing demand for advanced battery materials through its decades of materials expertise, longstanding relationships with many of the world’s leading battery manufacturers, global manufacturing footprint, and broad portfolio of conductive carbons, carbon nanotubes, and carbon nanostructures. Together, these capabilities enable the company to scale production efficiently, support customers with localized supply, and compete across the major battery markets of North America, Europe, and Asia.

“This investment represents an important step in our strategy to build a differentiated battery materials business that supports some of the most significant growth trends shaping the global economy,” said Sean Keohane, president and chief executive officer of Cabot Corporation. “Demand for advanced batteries continues to expand across energy storage, electrification, and emerging AI-related infrastructure. By leveraging our existing manufacturing assets, we can efficiently expand our battery materials platform, strengthen our position in the North American battery ecosystem, and support our customers’ growth with localized supply.”

Cabot’s planned investments will support production of LITX^® advanced battery-grade conductive carbons at its Franklin, Louisiana facility and establish the first commercial-scale production of carbon nanostructures (CNS), Cabot’s most advanced conductive additive technology and part of the ENERMAX™ product family, at its Pampa, Texas facility. These conductive additives are designed to help improve battery performance and support the evolving needs of next-generation energy storage and electrification applications. Both projects are expected to be operational by the end of 2028.

“Cabot is a trusted partner and technology leader in conductive additives for the battery industry, delivering innovative solutions backed by a global manufacturing footprint and technical expertise,” said Keohane. “These investments reinforce our commitment to the North American battery market and position us to be a reliable, long-term supplier as our customers scale production. Together with our technology leadership, broad portfolio, and established customer relationships, we believe these investments will strengthen our competitive position globally and advance battery materials as an increasingly important growth platform for Cabot.”

For more information about Cabot’s battery materials portfolio, visit cabotcorp.com/batteries.

About Cabot Corporation
Cabot Corporation (NYSE: CBT) is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. The company is a leading provider of reinforcing carbons, specialty carbons, battery materials, engineered elastomer composites, inkjet colorants, masterbatches and conductive compounds, fumed metal oxides and aerogel. For more information on Cabot, please visit the company’s website at cabotcorp.com.

Forward Looking Statement
This press release contains forward-looking statements. All statements that address expectations or projections about the future, including with respect to the planned expansion of the Company’s North America battery materials platform and expectations for future performance, growth and value creation for stockholders from these investments, are forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties, potentially inaccurate assumptions, and other factors, some of which are beyond our control and difficult to predict. If known or unknown risks materialize, or should underlying assumptions prove inaccurate, our actual results could differ materially from past results and from those expressed or implied by forward-looking statements. Important factors that could cause our results to differ materially from those expressed or implied in the forward-looking statements include, but are not limited to: the inherent uncertainty of capacity investments, the ability of the Company to successfully execute its planned production expansions, and the accuracy of the Company’s assumptions supporting these capital investments; industry capacity utilization and competition from other specialty chemical companies; safety, health and environmental requirements and related constraints imposed on our business; regulatory and financial risks related to climate change developments; volatility in the price and availability of energy and raw materials; negative or uncertain worldwide or regional economic conditions and market opportunities, including from trade relations, global health matters or geo-political conflicts; failure to achieve growth expectations from new products, applications and technology developments; failure to realize benefits from acquisitions, alliances, or joint ventures or achieve our portfolio management objectives; litigation or legal proceedings; interest rates, tax rates, currency exchange controls, tariffs and fluctuations in foreign currency rates; and other risks and uncertainties described in the reports we file with the Securities and Exchange Commission (“SEC”). These factors are discussed more fully in the reports we file with the SEC, particularly under the heading “Risk Factors” in our annual report on Form 10-K for our fiscal year ended September 30, 2025, which is filed with the SEC and available at www.sec.gov. We assume no obligation to provide revisions to any forward-looking statements should circumstances change, except as otherwise required by securities and other applicable laws.

Contact:
Vanessa Craigie
Corporate Communications
vanessa.craigie@cabotcorp.com
(617) 342-6015

Robert Rist
Investor Relations
robert.rist@cabotcorp.com
(617) 342-6374

Order covers unmanned aerial systems and associated support. A separate memorandum frames expanded cooperation, subject to definitive agreements and government approvals

• Limited procurement order received from the Ministry of Defence of the Islamic Republic of Pakistan for unmanned aerial systems and associated support.

• Order represents an expansion of Powerus’s international defense business.

• Separate memorandum of understanding frames expanded cooperation in unmanned and autonomous systems, subject to definitive agreements and government approvals.

• Powerus delegation received by the Chief of Army Staff at General Headquarters, Rawalpindi, per a statement issued by Inter-Services Public Relations.

• Powerus has entered into a definitive merger agreement with Aureus Greenway Holdings Inc. (Nasdaq: PUSA). The proposed merger remains subject to customary closing conditions.

WEST PALM BEACH, Fla., Sept. 17, 2026 (GLOBE NEWSWIRE) — Autonomous Power Corporation, dba Powerus (“Powerus”), a U.S. defense technology company focused on autonomous and unmanned systems, today announced that it has received a limited procurement order from the Ministry of Defence of the Islamic Republic of Pakistan for unmanned aerial systems and associated support.

The order represents an expansion of Powerus’s international defense business. No other terms of the order have been disclosed.

Powerus has also signed a strategic memorandum of understanding with senior defense officials of the Islamic Republic of Pakistan. The memorandum establishes a framework for potential expanded cooperation in unmanned and autonomous defense technologies and provides a basis for the parties to explore additional areas of cooperation and potential future deployment of Powerus systems. The memorandum is not a definitive agreement, creates no purchase obligation, and does not obligate either party to proceed. Any program or procurement contemplated under the framework would be subject to definitive agreements and to all applicable United States laws and regulations and government approvals.

On September 16, 2026, a Powerus delegation led by Co-Founder Brett Velicovich was received by Field Marshal Syed Asim Munir, Chief of Army Staff and Chief of Defence Forces, at General Headquarters in Rawalpindi. In a statement issued by Inter-Services Public Relations, the media wing of the Pakistan Armed Forces, the meeting was described as covering matters of mutual interest, evolving trends in defence technology, and avenues for cooperation in defence procurement, production and capacity building. The statement said both sides expressed interest in further developing engagement in areas of mutual interest.

“This is an important milestone for Powerus as we expand our international defense footprint,” said Brett Velicovich, Co-Founder of Powerus. “We are proud to support Pakistan’s Ministry of Defence, and the memorandum gives both sides a strategic framework to build upon.”

About Powerus

Powerus (Autonomous Power Corporation) builds and scales unified autonomous systems designed to move, protect, and sustain critical assets in high-risk environments, with capabilities spanning heavy-lift platforms, autonomous air systems, autonomous maritime systems, mission systems, training and support, and U.S.-based manufacturing. Powerus previously announced a proposed merger with AGH (Nasdaq: PUSA); the merger has not closed and remains subject to the satisfaction of customary closing conditions and applicable regulatory approvals. Learn more at power.us.

Proposed Merger

Powerus has previously announced a proposed merger with Aureus Greenway Holdings Inc. (Nasdaq: PUSA). Under the terms of the previously announced agreement, Powerus will merge with and into a newly formed subsidiary of AGH, with Powerus continuing as the surviving entity and AGH adopting the name “Powerus Corporation.” AGH has changed its Nasdaq ticker to PUSA in anticipation of its pending combination with Powerus, expected to close in the fourth quarter of 2026, subject to customary closing conditions and receipt of required regulatory approvals. There can be no assurance that the proposed transactions will be consummated or as to the timing of any such consummation.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. As to the order and the memorandum of understanding, these statements include but are not limited to statements regarding the order, the scope and performance of the order, the memorandum of understanding, the cooperation it contemplates, and the possibility that the parties may enter into definitive agreements in the future. Forward-looking statements may be identified by terminology such as “may,” “will,” “should,” “targets,” “plans,” “intends,” “goal,” “anticipates,” “expects,” “believes,” “potential,” or “continue” or negatives of such terms or other comparable terminology. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially.

As to the proposed business combination between Powerus and AGH, these statements include, without limitation, statements regarding the proposed merger between Powerus and AGH; the anticipated benefits of the merger; the expected timing of the completion of the merger; the anticipated listing and trading of the combined company’s securities; future financial and operating results; the plans, objectives, expectations and intentions of either company or of the combined company following the merger; anticipated future results of either company or of the combined company following the merger; and the anticipated benefits and strategic and financial rationale of the merger and other statements that are not historical facts and its expected timing.

All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from any results expressed or implied by such forward-looking statements. As to the order and the memorandum of understanding described in this release, such factors include, without limitation: (1) that required authorizations under United States export control laws, including the International Traffic in Arms Regulations, the Export Administration Regulations, and applicable sanctions programs, may be delayed, limited, conditioned, or denied, and that no assurance can be given that any authorization will be granted; (2) that the memorandum is not a definitive agreement and may never result in any further order, contract, revenue, or definitive agreement; (3) that the parties may not agree on the terms of any definitive agreement; (4) that cooperation contemplated by the memorandum may never be authorized or implemented; (5) that United States foreign policy, licensing policy, or congressional review may change; (6) that the customer’s procurement priorities or funding may change; (7) that delivery may be delayed by supply chain, production, or logistics conditions; (8) that either party may terminate or decline to proceed; (9) that the order may be cancelled or amounts received may become refundable; and (10) that activity under the order or the memorandum may expose Powerus to regulatory, reputational, or geopolitical risk, including consequences for commercial relationships in other markets.

As to the announced merger agreement, such factors include, among others: (1) the risk of delays in consummating the potential transaction, including as a result of required regulatory approvals, including Nasdaq listing requirements which may not be obtained on the expected timeline, or at all; (2) the risk of any event, change or other circumstance that could give rise to the termination of the merger agreement; (3) the possibility that any of the anticipated benefits and projected synergies of the potential transactions will not be realized or will not be realized within the expected time period; (4) the limited operational history of Powerus as a combined organization and integration risks of acquired businesses; (5) diversion of management’s attention or disruption to the parties’ businesses as a result of the announcement and pendency of the transaction, including potential distraction of management from current plans and operations of AGH or Powerus and the ability of AGH or Powerus to retain and hire key personnel; (6) reputational risk and the reaction of each company’s customers, suppliers, employees or other business partners to the transaction; (7) the possibility that the transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events; (8) the outcome of any legal or regulatory proceedings that may be instituted against AGH or Powerus related to the merger agreement or the transaction; (9) the risks associated with third party contracts containing consent and/or other provisions that may be triggered by the proposed transaction; (10) legislative, regulatory, political, market, economic and other conditions, developments and uncertainties affecting AGH’s or Powerus’s businesses; (11) the evolving legal, regulatory, tax, and international trade regimes; (12) the nature, cost and outcome of potential litigation and other legal proceedings, including any such proceedings related to the transactions; (13) restrictions during the pendency of the proposed transaction that may impact AGH’s or Powerus’s ability to pursue certain business opportunities or strategic transactions; and (14) unpredictability and severity of catastrophic events, including, but not limited to, extreme weather, natural disasters, acts of terrorism or outbreak of war or hostilities, as well as AGH’s and Powerus’s response to any of the aforementioned factors.

In connection with the proposed merger, AGH has filed relevant materials with the SEC, including a registration statement on Form S-4, which includes an information statement prospectus, and may file additional materials in the future. Investors and security holders are urged to read those materials because they contain important information. Forward-looking statements speak only as of the date of this release, and except as required by law, neither company undertakes any obligation to update them. This release does not constitute an offer to sell or the solicitation of an offer to buy any securities.

No Offer or Solicitation

This document is for informational purposes only and is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

Important Information and Where to Find It

In connection with the transaction, AGH has filed a registration statement on Form S-4 with the SEC, which includes an information statement and prospectus of AGH, and has mailed a definitive information statement and prospectus to its stockholders. Investors and security holders are urged to read the registration statement (and any other documents filed with the SEC in connection with the transaction or incorporated by reference into the registration statement) because such documents contain important information regarding the proposed transaction and related matters. Investors and security holders may obtain free copies of these documents and other documents filed with the SEC by AGH through the website maintained by the SEC at http://www.sec.gov or at AGH’s website at https://www.aureusgreenway.com/secfilings.

Contacts

AGH Investor Relations
Jason Assad
678-570-6791

Powerus Press Contact
Escalate PR
pr@power.us

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/df05bd19-19a7-47c8-a42e-a09f63f4641b

Geneva, Switzerland and Taipei, Taiwan, Sept. 17, 2026 (GLOBE NEWSWIRE) —

Design win brings QVault TPM183 into commercial production designs and extends SEALSQ’s established healthcare franchise from medical devices to the clinician workstation

SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or the “Company”), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced that iMTC Technology, a Taiwan-based provider of fingerprint recognition and medical input solutions, has selected SEALSQ’s QVault TPM183 for its next-generation Fingerprint Recognition Medical Mouse designed for hospitals and healthcare environments.

The collaboration combines fingerprint recognition technology with SEALSQ’s trusted hardware security technology to provide a secure and convenient authentication solution. The Fingerprint Recognition Medical Mouse supports Windows Enhanced Sign-in Security (ESS) and Windows Hello, enabling healthcare professionals to authenticate through fingerprint recognition when accessing medical workstations and healthcare applications. Primarily designed to be used for medical workstations, the device is also matching the needs to authenticate workstation users across industrial manufacturing, education and research, logistics, government services and banking.

Carlos Moreira, CEO of SEALSQ noted, “SEALSQ already secures healthcare at the device and card level. TPM183 now adds the workstation layer, which means we can address a hospital’s full trust chain, patient credential, medical device, and clinician login, with one root-of-trust architecture. That breadth is what makes healthcare a durable, multi-product market for us rather than a single design win.”

“We evaluated several security providers and selected SEALSQ because TPM183 gave us three things at once: a certified TPM 2.0 root of trust, native support for Windows Enhanced Sign-in Security, and a defined migration path to post-quantum cryptography. Hospitals buy equipment for a decade, so our customers need confidence that the security in the device today will still be credible against tomorrow’s threats. SEALSQ let us design that in from the start.”

The iMTC Fingerprint Recognition Medical Mouse product family includes four configurations:

1. iM-FRM-2608A – Basic Version: Fingerprint Recognition Mouse supporting Windows ESS and Windows Hello.
2. iM-FRM-2608TPM – TPM Version: Integrates SEALSQ TPM183 with TPM 2.0 architecture, supporting Windows ESS and Windows Hello and providing hardware-based protection for cryptographic keys and device identity. The platform also provides a roadmap toward future Post-Quantum Cryptography (PQC) support.
3. iM-FRM-2608SE – Secure Element Version: Integrates a customizable Secure Element and supports Windows ESS, Windows Hello and advanced cryptographic functions.
4. iM-FRM-2608QS – Security MCU Version: Integrates a Security MCU with Windows ESS, Windows Hello and FIDO2 support.

Large Market Opportunity

Hospitals operate large fleets of shared workstations that require frequent, auditable clinician sign-on, and tightening data-protection and medical-device cybersecurity requirements are moving authentication from software-only credentials toward hardware-anchored roots of trust. Each TPM-enabled unit represents semiconductor content for SEALSQ, and healthcare IT refresh cycles create a recurring replacement base. SEALSQ’s chips are already used to read patient cards in terminals deployed by major European national healthcare systems, and its secure elements and PKI secure connected medical devices and remote patient monitoring.

The TPM-enabled version provides a hardware-based root of trust that protects cryptographic keys and login credentials in shared hospital environments, where doctors, nurses and technicians repeatedly access common workstations, electronic medical records and patient information systems.

Embedding fingerprint recognition in the mouse secures that access without changing clinician workflow, a common barrier to adoption in hospital IT. Anchoring authentication in SEALSQ silicon also gives iMTC a path to evolving cybersecurity requirements, including the transition to post-quantum cryptography.

About iMTC Technology

iMTC is a Taiwan-based technology company specializing in Industrial & Medical input solutions, fingerprint recognition, and biometric authentication. The company develops innovative input devices designed to improve authentication, security and usability in healthcare and other security-sensitive environments. For more information, please visit www.imtc.com.tw

About SEALSQ:
SEALSQ is a leading innovator in Post-Quantum Technology hardware and software solutions. Our technology seamlessly integrates Semiconductors, PKI (Public Key Infrastructure), and Provisioning Services, with a strategic emphasis on developing state-of-the-art Quantum Resistant Cryptography and Semiconductors designed to address the urgent security challenges posed by quantum computing. As quantum computers advance, traditional cryptographic methods like RSA and Elliptic Curve Cryptography (ECC) are increasingly vulnerable.

SEALSQ is pioneering the development of Post-Quantum Semiconductors that provide robust, future-proof protection for sensitive data across a wide range of applications, including Multi-Factor Authentication tokens, Smart Energy, Medical and Healthcare Systems, Defense, IT Network Infrastructure, Automotive, and Industrial Automation and Control Systems. By embedding Post-Quantum Cryptography into our semiconductor solutions, SEALSQ ensures that organizations stay protected against quantum threats. Our products are engineered to safeguard critical systems, enhancing resilience and security across diverse industries.

For more information on our Post-Quantum Semiconductors and security solutions, please visit www.sealsq.com.

Forward-Looking Statements
This communication expressly or implicitly contains certain forward-looking statements concerning SEALSQ Corp and its businesses. Forward-looking statements include statements regarding our business strategy, financial performance, results of operations, market data, events or developments that we expect or anticipate will occur in the future, as well as any other statements which are not historical facts. Although we believe that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates which are inherently subject to significant uncertainties and contingencies, many of which are beyond our control. Actual results may differ materially from those expressed or implied by such forward-looking statements. Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include SEALSQ’s ability to continue beneficial transactions with material parties, including a limited number of significant customers; market demand and semiconductor industry conditions; and the risks discussed in SEALSQ’s filings with the SEC. Risks and uncertainties are further described in reports filed by SEALSQ with the SEC.

SEALSQ Corp is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

SEALSQ Corp. Carlos Moreira Chairman & CEO Tel: +41 22 594 3000 info@sealsq.com

SEALSQ Investor Relations (US) The Equity Group Inc. Lena Cati Tel: +1 212 836-9611 lena.cati@theequitygroup.com

• The gateway marks a key milestone in the deployment of Telesat Lightspeed, Telesat’s next-generation low Earth orbit (LEO) satellite constellation.
• The Telesat Lightspeed gateway, hosted at Orange’s teleport in Bercenay-en-Othe, France, is now installed and commissioned.
• Orange provides ground connectivity to Telesat’s planned point of presence (PoP) in Paris.
• This new gateway is expected to significantly boost secure, reliable, and low-latency connectivity for enterprise and government clients across Europe

PARIS and OTTAWA, Ontario, Sept. 17, 2026 (GLOBE NEWSWIRE) — September 17, 2026 – Orange, one of the world’s leading telco operators and digital service providers, and Telesat LEO ULC, a subsidiary of Telesat Corporation (Nasdaq and TSX: TSAT), one of the world’s largest and most innovative satellite operators, today announced the commissioning of the first European gateway for the Telesat Lightspeed constellation.

Hosted within Orange’s World Teleport Association Tier-4 certified teleport in Bercenay-en-Othe, France, this state-of-the-art gateway is a key component of Telesat’s terrestrial infrastructure and will support the deployment of the planned initial 225 satellites that will form the Telesat Lightspeed constellation.

Ground segment connectivity will be provided by Orange through a secure high-speed network connecting the station to Telesat’s planned point of presence (PoP) in Paris, delivering the high availability and low latency required for mission-critical applications. The selection of Bercenay-en-Othe was driven by operational excellence, security certifications, and the ability to rapidly integrate cutting-edge technologies.

Telesat is designing its Telesat Lightspeed network to deliver enterprise-grade connectivity with the security, resilience, and performance required for mission-critical operations. The Bercenay-en-Othe gateway includes advanced gateway antennas supplied by Intellian Technologies, supporting the network’s high-capacity, low-latency architecture. Leveraging optical inter-satellite links, the Telesat Lightspeed network is being designed to enable customer traffic to remain in space until it is securely delivered to a Telesat landing station or a customer’s private landing facility, providing enterprise, telecom, government, and defence users with enhanced data sovereignty, routing flexibility and control.

“We are very pleased to host this new low Earth orbit gateway in our Bercenay-en-Othe teleport. This partnership with Telesat demonstrates our ability to deliver trusted ground infrastructure as well as innovative and resilient connectivity solutions with our integration of next-generation satellite networks. The activation of this gateway not only reinforces our position in the space ecosystem but also supports our efforts to address the increasing demand for secure satellite connectivity. Additionally, this collaboration aligns with our goal to host more satellite operators at Bercenay-en-Othe through our ground segment offerings, establishing the site as a European hub for the next generation of satellite networks,” said Jean-Louis Le Roux, EVP Orange International Networks.

“As we continue the build-out of the Telesat Lightspeed terrestrial infrastructure in advance of our anticipated global in-service date of Q1 2028, Orange is a valued strategic partner in our deployment efforts. We look forward to exploring additional opportunities for collaboration that will support the delivery of resilient connectivity, including for Orange’s customers across Europe, Africa and other locations around the world,” added Telesat’s Chief Commercial Officer Glenn Katz.

As a key component of Orange’s global connectivity network, the Bercenay-en-Othe teleport plays a crucial role in delivering tailored, reliable, and low-latency connectivity solutions. By leveraging Telesat’s cutting-edge satellite technology alongside Orange’s 60 years of expertise in satellite connectivity and ground segment capabilities, this collaboration enhances the resilience of global digital infrastructure, improves coverage, and promotes digital inclusion in remote areas.

About Orange
Orange is one of the world’s leading telecommunications operators. The Group aims to be the trusted partner for everyday digital life by providing individuals, businesses and communities with reliable connectivity and innovative services. As of the end of 2025, Orange connects 340 million customers (including MasOrange) across 26 countries and generated 40.4 billion euros in revenues.

As a trusted player, Orange leverages the excellence of its very high-speed broadband networks to deploy digital infrastructure in Europe, Africa and the Middle East. The Group is a European leader in fiber, with 100 million connectable households, and convergent offers. In France, Orange connects 34 million customers and was ranked No. 1 by the regulator Arcep for the quality of its mobile network for the 15th consecutive year. In Africa and the Middle East, the Group’s growth engine, Orange serves nearly 180 million customers and promotes digital and financial inclusion through its connected solutions.

Under the Orange Business brand, the Group supports companies in transforming their networks as well as in AI, trusted cloud and cybersecurity. Orange is also a major player in the wholesale market, where it has a leading global telecom infrastructure and significant capabilities for deploying and operating submarine cables. A committed innovator, Orange relies on 700 researchers and holds a portfolio of 11,000 patents.

Orange is listed on Euronext Paris (symbol ORA).

For more information on the internet and on your mobile: www.orange-business.com

Orange and any other Orange product or service names included in this material are trademarks of Orange or Orange Brand Services Limited.

Orange contacts
Fatima Rahil – fatima.rahil@orange.com

Krista Stephens – krista.stephens@orange.com

About Telesat
Telesat Corporation (Nasdaq and TSX: TSAT) (“Telesat”) is a global satellite operator and leader in advanced satellite communications, redefining broadband connectivity through its Telesat Lightspeed Low Earth Orbit (LEO) network.

Designed from inception for interoperability with enterprise and government applications, Telesat Lightspeed delivers secure, resilient, high-performance broadband connectivity with fibre-like speeds. Its advanced, software-defined architecture operates in both commercial and military Ka-band spectrum, enabling mission-critical communications with enhanced security and protection against evolving threats. Purpose-built to meet the most demanding requirements, Telesat Lightspeed provides telecom, enterprise, aviation, maritime and defence customers with unprecedented flexibility and control to dynamically manage their own services and deliver differentiated, end-to-end connectivity solutions worldwide.

With nearly 60 years of innovation, engineering excellence and a collaborative approach to customer success, Telesat is uniquely positioned to deliver secure, scalable and future-ready connectivity solutions that help customers solve their most complex communications challenges and achieve mission success. For updates on Telesat, follow us on LinkedIn, X, or visit http://www.telesat.com.

Telesat Contacts

Monique Scotti: pr@telesat.com

W2 Communications for Telesat: telesat@w2comm.com

Telesat’s forward-Looking Statements Safe Harbor

This news release contains statements that are not based on historical fact and are “forward-looking statements’’ and “forward looking information” within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities laws, including statements regarding Telesat’s planned Lightspeed network, its commercial availability and performance, and its market demand. When used herein, statements which are not historical in nature, or which contain the words “will,” “can,” “planned,” “designing,” “anticipated,” “expected” or similar expressions, are forward-looking statements. In addition, Telesat or its representatives have made or may make forward-looking statements, provide forward looking information, orally or in writing, which may be included in, but are not limited to, various filings made from time to time with the U.S. Securities and Exchange Commission (“SEC”) and Canadian securities regulatory authorities, and news releases or oral statements made with the approval of an authorized executive officer of Telesat. All statements made in this news release are made only as of the date set forth at the beginning of this news release. Telesat undertakes no obligation to update the statements made in this news release in the event facts or circumstances subsequently change after the date of this news release.

These forward-looking statements and this forward-looking information are not guarantees of future performance, are based on Telesat’s current expectations, and are subject to a number of known and unknown risks, uncertainties assumptions, and other factors, some of which are beyond Telesat’s control, are difficult to predict, and could cause actual results to differ materially from those expressed, forecasted or implied in the forward-looking statements and forward looking information.

Forward-looking statements involve risks, contingencies and uncertainties, which are difficult to predict and many of which are beyond Telesat’s control. These risks, contingencies, and uncertainties and other important risks and factors are discussed in Telesat Corporation’s annual report on Form 20-F for the year ended December 31, 2025 that was filed on March 17, 2026 with the SEC and the Canadian securities regulatory authorities at the System for Electronic Document Analysis and Retrieval+ (“SEDAR+”), and may be accessed on the SEC’s website at www.sec.gov and SEDAR+’s website at www.sedarplus.ca as well as our subsequent reports on Form 6K filed with the SEC and also available on SEDAR.